KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Financing Activities: 2009-2024

Historic Cash from Financing Activities for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to -$218.9 million.

  • Halozyme Therapeutics' Cash from Financing Activities fell 220.69% to -$22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$571.1 million, marking a year-over-year decrease of 156.83%. This contributed to the annual value of -$218.9 million for FY2024, which is 46.36% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Cash from Financing Activities stood at -$218.9 million for FY2024, which was up 46.36% from -$408.0 million recorded in FY2023.
  • Over the past 5 years, Halozyme Therapeutics' Cash from Financing Activities peaked at $362.4 million during FY2022, and registered a low of -$408.0 million during FY2023.
  • For the 3-year period, Halozyme Therapeutics' Cash from Financing Activities averaged around -$88.2 million, with its median value being -$218.9 million (2024).
  • As far as peak fluctuations go, Halozyme Therapeutics' Cash from Financing Activities soared by 365.38% in 2022, and later tumbled by 212.59% in 2023.
  • Halozyme Therapeutics' Cash from Financing Activities (Yearly) stood at -$106.3 million in 2020, then skyrocketed by 173.26% to $77.9 million in 2021, then soared by 365.38% to $362.4 million in 2022, then tumbled by 212.59% to -$408.0 million in 2023, then skyrocketed by 46.36% to -$218.9 million in 2024.